Pfizer

As of 2026-11-06, Pfizer (₹3,857.0) exhibits a conflicting technical structure: short-term momentum is positive while the broader trend remains bearish. The stock has surged +6.8% over the past 10 days, driven by extreme anomalies including a volume-backed move on 2026-11-03 and an upward gap on 2026-11-05. This recent strength places the price above its 20-day EMA and SMA, with a daily ADX of 29.41 indicating established short-term trend strength. However, the price remains below key longer-term averages (50-day and 200-day SMAs) and the Supertrend across daily, weekly, and monthly timeframes. The monthly ADX is weak at 12.62, suggesting the primary downtrend lacks conviction but persists. The stock trades near the lower end of its 252-day range (+15.3%) and carries a significant current drawdown of -34.5%. Immediate resistance lies at ₹3,865.53 (pivot), with support at ₹3,826.37.

Pfizer India reported its Q2 results on November 3, 2026, revealing a significant surge in profitability driven by non-operational factors. The company posted a net profit of ₹313 crore, marking a 65.6% year-on-year increase. This jump was primarily attributable to a one-time gain of ₹132 crore. On the top line, revenue grew 13.2% to ₹727 crore, while EBITDA expanded 14.4% to ₹262 crore. Despite the earnings growth, the EBITDA margin remained flat at 36%, indicating that operational efficiency did not improve proportionally with revenue. Following these disclosures, Pfizer’s shares on the BSE rose 3.37%. In broader market context, Pfizer was listed among key global entities reporting earnings during the week of November 2–6, alongside peers such as Apple and Amgen.

Pfizer Limited’s Board approved unaudited financial results for the quarter and half-year ended September 30, 2026, reporting revenue from operations of ₹726.86 crore and a net profit of ₹313.25 crore. The profit figure includes a significant one-time exceptional item of ₹132.06 crore, which is a lump-sum payment received from Pfizer Inc. USA following the discontinuation of Minipress XL marketing and distribution effective September 7, 2026. This product withdrawal stems from a manufacturing decision by Pfizer Inc. USA.

Statutory auditor B S R & Co. LLP issued an unmodified limited review report, confirming no material misstatements or compliance issues were identified in these results. Separately, the company disclosed receipt of an Income Tax Transfer Pricing order dated September 25, 2026, levying a penalty of Rs. 1,26,34,050 for alleged non-furnishing of granular information during the Assessment Year 2023-24 audit. Pfizer Limited considers this order not maintainable and is preparing to appeal, asserting that the penalty will have no material impact on its financial position or operations.

Pfizer’s operating trajectory has strengthened significantly in the most recent reported periods, marked by robust top-line growth and improving profitability. For Q2 FY2026-27 (ended September 2026), revenue from operations rose sequentially to ₹727 crore, while net profit more than doubled to ₹313 crore compared to ₹204 crore in Q1. This acceleration is supported by a sharp rise in other income to ₹179 crore in the quarter, contributing to a Profit Before Tax of ₹423 crore. On an annualized basis, the company posted TTM sales of ₹2,654 crore with a 12% compounded sales growth rate over the trailing twelve months, alongside a strong Return on Equity of 18%.

Financial health remains solid, with ROCE improving to 24% in Mar 2026 and working capital efficiency notably enhancing as Working Capital Days dropped sharply to 9 days. However, cash flow dynamics show a divergence: while Cash from Operating Activity surged to ₹968 crore in Mar 2026, Cash from Financing Activity turned deeply negative at -₹798 crore, likely reflecting debt repayment or shareholder returns. Concurrently, cash reserves declined from ₹205 crore to ₹92.8 crore by September 2026. Ownership structure is stable, with promoters holding 63.92% and DIIs increasing their stake slightly to 17.52%, while FIIs reduced theirs to 1.63%.

The key checkpoint for the next period is monitoring whether the surge in 'Other Income' sustains net profit margins and if the heavy financing outflows continue without straining liquidity, given the drop in cash balances.

Pfizer India demonstrated operational resilience in Q2 FY2026, with revenue rising 13.2% year-on-year to ₹727 crore and EBITDA expanding 14.4% to ₹262 crore. The company maintained a stable EBITDA margin of 36%, indicating effective cost management despite top-line growth. Net profit surged 65.6% to ₹313 crore, primarily driven by a one-time gain of ₹132 crore, which supported a positive market reaction with the BSE share price rising 3.37%. While technical indicators across daily, weekly, and monthly timeframes remain bearish, with the stock trading near recent lows and showing negative slope trends, the fundamental earnings beat provides a conditional basis for constructive interpretation. This upside case is contingent on the sustainability of organic revenue growth and margin stability, rather than the non-recurring financial event that inflated profits.

Pfizer’s recent performance on the NSE reveals a divergence between reported profitability and underlying operational momentum, alongside significant technical deterioration. While Q2 net profit rose 65.6% year-on-year to ₹313 crore, this surge was primarily driven by a one-time gain of ₹132 crore; without this item, organic growth appears muted. Revenue grew modestly at 13.2% to ₹727 crore, and EBITDA margin remained flat at 36%, indicating limited pricing power or cost efficiency gains despite top-line expansion.

Technically, the stock is under sustained pressure. The daily Supertrend is bearish, with the 20-day EMA slope negative (-0.42) and the 50-day SMA slope sharply declining (-108.97). Momentum indicators show selling dominance, with the Minus DI (24.05) exceeding the Plus DI (21.99). The stock has suffered a severe drawdown, currently down -34.5% from its peak, with a maximum historical drawdown of -38.7%. Year-to-date returns are deeply negative at -21.5%, and the one-year return stands at -23.9%. Volatility remains elevated at an annualized 25.9%, suggesting continued uncertainty. Immediate resistance sits tightly at ₹3,865.53, just 0.22% above the current close of ₹3,857.0, while support levels at ₹3,826.37 and ₹3,795.83 offer limited cushion against further downside.